Suki, a startup that makes an AI-powered and voice-enabled digital assistant for doctors, has just landed $20 million in a funding round led by Venrock, with participation from First Round, Social Capital, and Marc Benioff.
Fitbit announced yesterday that it plans to utilize Google’s new Cloud Healthcare API, in order to continue its push into the world of serious healthcare devices. It’s a bit of a no-brainer as far as partnerships go.
The Food and Drug Administration plans to launch a full-scale version of its digital health precertification program by the end of the year.
IDx, a privately held AI diagnostics company, announced today that it has filed its De Novo submission to the FDA for IDx-DR, an AI-based system for the autonomous detection of diabetic retinopathy — a leading cause of blindness. The FDA has granted IDx-DR with a “Breakthrough Device” designation, which means the submission will receive expedited review.
On Tuesday, Bothell, Washington-based Steth IO announced the launch of its smartphone-based digital stethoscope.
The mHealth app, designed by researchers at the Worcester Polytechnic Institute, helps obstetric care providers identify perinatal depression in soon-to-be and new mothers and gives them care management tips.
A recent study of so-called 'white coat hypertension' finds that blood pressure readings taken at the doctor's office can be less accurate and more dangerous than readings taken at home with mHealth devices.
A recent report from Accenture analyzed the “near-term value” of AI applications in health care to determine how the potential impact of the technology stacks up against the upfront costs of implementation. Results from the report estimated that AI applications in health care could save up to $150 billion annually for the U.S. health care economy by 2026.
The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meeting
Using the device, called a Beam, Miramont Family Medicine now sees more patients than ever – enabling physicians to be in more than one of its four locations at the same time.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.